Vaxart updates BARDA funding for COVID-19 oral vaccine trial
Vaxart received additional BARDA funding to advance COVID-19 vaccine data analysis. The release allows the company to report 12-month trial data.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day